Cargando…
ERCC6L facilitates the onset of mammary neoplasia and promotes the high malignance of breast cancer by accelerating the cell cycle
BACKGROUND: Breast cancer (BC) is the leading cause of morbidity and the second leading cause of death among female malignant tumors. Although available drugs have been approved for the corresponding breast cancer subtypes (ER-positive, HER2(+)) currently, there are still no effective targeted drugs...
Autores principales: | Yang, Hong, Zhen, Xiangjin, Yang, Yihui, Zhang, Yizhi, Zhang, Sen, Hao, Yue, Du, Guanhua, Wang, Hongquan, Zhang, Bailin, Li, Wan, Wang, Jinhua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10478442/ https://www.ncbi.nlm.nih.gov/pubmed/37667329 http://dx.doi.org/10.1186/s13046-023-02806-x |
Ejemplares similares
-
Progress on diagnostic and prognostic markers of pancreatic cancer
por: YANG, HONG, et al.
Publicado: (2023) -
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis
por: Ren, Liwen, et al.
Publicado: (2022) -
Recent advances in epigenetic anticancer therapeutics and future perspectives
por: Ren, Liwen, et al.
Publicado: (2023) -
Sphingosine kinase 1 promotes growth of glioblastoma by increasing inflammation mediated by the NF-κB /IL-6/STAT3 and JNK/PTX3 pathways
por: Li, Wan, et al.
Publicado: (2022) -
Mammary gland neoplasia.
por: Neumann, D A, et al.
Publicado: (1996)